08.11.2012 09:08
Bewerten
(0)

Investment update on the Baring High Yield Bond Fund

The combination of robust fundamentals and high demand from investors has seen the high yield bond market go from strength to strength in recent months.

Since the beginning of the year, the Bank of America Merrill Lynch Global High Yield Index has returned +15.0% in US dollar terms, making high yield credit one of the better performing asset classes, not just within fixed income but across the broader investment universe.

In spite of this strong performance, we remain positive on the outlook for high yield bonds. In our view, issuers have manageable levels of leverage, with sensible maturity profiles, while corporate balance sheets are generally strong notwithstanding the challenging economic environment. In turn, this has helped to keep default rates low amongst issuers and below the long-term average. Moody’s and S&P predict default rates of just 3.1% and 3.3% respectively for year-end.

Even after the returns seen so far this year, the risk premium attached to high yield bonds remains too high in our view, reflecting a market consensus that default rates will be closer to 4% - 5%. We believe this is unduly pessimistic, on the basis of the forecasts from Moody’s and S&P. In our view, high yield bonds continue to present solid value at this level, offering investors coupon payments as well as the potential for capital growth.

In a world where dividends and yield are in short supply, we believe demand for high yield bonds will remain a further source of support for the asset class as we go forward from here. Not only do yields compare favourably with other asset classes, in our view, but an increasing amount of money is being allocated into high yield credits.

Rising demand has undoubtedly had an effect on market liquidity. Where we would previously take a new position in the Fund in one or two days, it might now take a week. However, we believe this is still acceptable. One of the reasons that issuers offer a more attractive level of yield is the liquidity of the issue – lower liquidity typically attracts a premium, and the high yield market has experienced these conditions before. Increased demand is also being met with a record level of issuance from corporates – US$220bn since the start of the year – which is going some way to meet growing interest.

We take liquidity risk seriously, and seek to manage it prudently through our investment process. We require new issues to be of a certain size before we will invest – US$400mn / Euro350mn. We reduce single issuer risk by holding on average 150 to 170 names in the Fund, with a maximum active position of no more than 0.9%. Consequently, we will rarely hold more  than 3% of a particular issue. Finally, we limit our exposure to lower-rated credits, potentially most exposed to liquidity risk, to no more than 10% of the portfolio. Our focus instead is on higher rated credits, typically in the B – BB band.

The combination of this approach with our longer-term investment horizon – our annual turnover is typically just 60% to 70% – means that current conditions are manageable, in our view, and we do not believe investors should be unduly concerned. In the meantime, we remain positive on the prospects for the asset class, and believe high yield continues to offer investors an attractive combination of income and potential for growth.

Das Investment Update im pdf-Dokument

powered by
€uro FundResearch

Fondsfinder

Suchen

Heute im Fokus

Starker Euro belastet DAX -- Dow schließt im Minus -- Microsoft steigert Gewinn -- Visa mit guten Quartalszahlen -- Anleger von eBay-Zahlen enttäuscht -- Hella im Fokus

Finanzinvestor Apollo will wohl Sicherheitsfirma ADT an die Börse bringen. EZB: Leitzins bleibt "auf längere Zeit" unverändert. SAP hebt Umsatzausblick an. ADVA kämpft mit starkem Wettbewerb. Sixt-Aktie auf Rekordhoch: Sixt erhöht Prognose. Draghi gibt keine Signale für Änderung der EZB-Geldpolitik.
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die Top 5 der Medizin- und Pharmakonzerne mit großen Wachstumschancen!

Aktien aus dem Medizin- und Pharmabereich gehören neben den hochtechnologischen Konzernen wohl zu den schwierigsten Wertpapieren, die man an der Börse spielen kann. Die meisten Unternehmen, die auf diesem Feld unterwegs sind, bleiben über Jahre hin unprofitabel. Wir stellen im aktuellen Anlegermagazin fünf Aktien vor, bei denen große Wachstumschancen lauern könnten.
Anlegermagazin kostenlos erhalten

Top-Rankings

Sorglos die Koffer packen
In diesen europäischen Ländern kommt man voll auf seine Kosten
KW 28: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten
E-Autos: Kein Zwang zum Tesla-Kauf
Diese Tesla-Konkurrenten sind auf dem Vormarsch und billiger als der Model 3

Umfrage

Bundeskanzlerin Angela Merkel lehnt eine Obergrenze für Flüchtlinge weiter ab. Sind Sie für eine solche Grenze?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln

Willkommen bei finanzen.net Brokerage

Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus finanzen.net

Weitere Informationen finden Sie hier.

Jetzt informieren


Sie haben bereits ein Depot? Dann verknüpfen Sie es jetzt mit Ihrem finanzen.net-Account!

Jetzt mit finanzen.net-Account verknüpfen

Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Lufthansa AG823212
Daimler AG710000
CommerzbankCBK100
Deutsche Bank AG514000
EVOTEC AG566480
Volkswagen (VW) AG Vz.766403
ADVA SE510300
Apple Inc.865985
TeslaA1CX3T
SAP SE716460
E.ON SEENAG99
Allianz840400
Siemens AG723610
Deutsche Telekom AG555750
Amazon906866